{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:15:12Z","timestamp":1788520512595,"version":"build-2803163510"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Non-Hodgkin lymphoma (NHL) includes pathologies of different clinical courses, treatments, outcomes. Our study aims to investigate the late effects of NHL survivors (NHLS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Among 59 NHL cases, 50 survivors completed their NHL treatment between 2003 and 2019. Out of 59 patients, the cumulative survival rates and event-free survival rates after 10 years since diagnosis were 82.9% \u00b15.2% and 84.1% \u00b15.2%, respectively. In addition, we compared the data related to chronic health and psychosocial conditions with their siblings (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 61).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The age and gender ratios were similar in the NHLS (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 50) and the control group (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 61). The rate of nephrotoxicity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02) and the frequency of admission to the hospital (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) were significantly higher in the survivors than in the control group. Cardiotoxicity is detected in 3 (6%) of NHLS with cumulative anthracycline dose &lt;300 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . The social status (being married [\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01], having children [\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003]) is impaired in NHLS. The alcohol and smoking habits, education status, and health conditions (endocrinologic, cardiac, neurological, and pulmonary) were similar in both groups. One patient had acute myeloid leukemia as a secondary malignancy. Twenty NHLS took rituximab, two of them took brentuximab vedotin plus chemotherapy. NHLS have impairment in health status, social life.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Nephrotoxicity is a statistically more common late effect than the others in the survivors. We observe cardiotoxicity in low cumulative doses of anthracycline. A more significant number of patients is required to reveal late side effects on novel drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_80_21","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T05:01:00Z","timestamp":1644469260000},"page":"712-717","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Late outcomes in children and adolescents with non-Hodgkin lymphoma: A single-center experience"],"prefix":"10.4103","volume":"18","author":[{"given":"Nurdan","family":"Tacyildiz","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice Mine","family":"\u00c7akmak","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"\u00dcnal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handan","family":"Din\u00e7aslan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer","family":"Kartal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl\u015fah","family":"Tany\u0131ld\u0131z","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonay &","family":"\u00d6zdemir","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclsan","family":"Yavuz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"R1-20250514","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/bjh.15775","article-title":"Long-term survivors of childhood, adolescent, and young adult non-Hodgkin lymphoma","volume":"185","author":"Ehrhardt","year":"2019","journal-title":"Br J Haematol"},{"key":"R2-20250514","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1055-9965.EPI-16-0520","article-title":"Cancer incidence and survival trends by subtype using data from the Surveillance Epidemiology and End Results Program, 1992\u20132013","volume":"26","author":"Noone","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R3-20250514","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/ijc.29135","article-title":"Late mortality among 5-year survivors of early-onset cancer: A population-based register study","volume":"136","author":"Kero","year":"2015","journal-title":"Int J Cancer"},{"key":"R4-20250514","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(18)30537-0","article-title":"Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: A report from the Childhood Cancer Survivor Study cohort","volume":"19","author":"Gibson","year":"2018","journal-title":"Lancet Oncol"},{"key":"R5-20250514","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0140-6736(17)31610-0","article-title":"The cumulative burden of surviving childhood cancer: An initial report from the St Jude Lifetime Cohort Study (SJLIFE)","volume":"390","author":"Bhakta","year":"2017","journal-title":"Lancet"},{"key":"R6-20250514","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-Hodgkin lymphoma in children and adolescents: Progress through effective collaboration, current knowledge, and challenges ahead","volume":"33","author":"Minard-Colin","year":"2015","journal-title":"J Clin Oncol"},{"key":"R7-20250514","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mpo.1316","article-title":"Study design and cohort characteristics of the Childhood Cancer Survivor Study: A multi-institutional collaborative project","volume":"38","author":"Robison","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"R8-20250514","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Soci\u00e9t\u00e9 Fran\u00e7aise d'Oncologie P\u00e9diatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"R9-20250514","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bjh.14035","article-title":"Childhood, adolescent and young adult non-Hodgkin lymphoma: State of the science","volume":"173","author":"Cairo","year":"2016","journal-title":"Br J Haematol"},{"key":"R10-20250514","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/pbc.24975","article-title":"Improved treatment results of children with B-cell non-Hodgkin lymphoma: A report from the Japanese Pediatric Leukemia\/Lymphoma Study Group B-NHL03 study","volume":"61","author":"Tsurusawa","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20250514","doi-asserted-by":"crossref","first-page":"e26338","DOI":"10.1002\/pbc.26338","article-title":"Late outcomes of adult survivors of childhood non-Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort Study","volume":"64","author":"Ehrhardt","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20250514","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2019-129558","article-title":"Prevalence of chronic kidney disease (CKD) in lymphoma survivors","volume":"134","author":"Al-Shbool","year":"2019","journal-title":"Blood"},{"key":"R13-20250514","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2265.2008.03283.x","article-title":"Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL)","volume":"69","author":"Steffens","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R14-20250514","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer"},{"key":"R15-20250514","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/cncr.11117","article-title":"Utilization of special education services and educational attainment among long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study","volume":"97","author":"Mitby","year":"2003","journal-title":"Cancer"},{"key":"R16-20250514","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/pbc.23363","article-title":"Gonadal function and parenthood 20 years after treatment for childhood lymphoma: A cross-sectional study","volume":"59","author":"Hamre","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20250514","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.290.12.1583","article-title":"Health status of adult long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study","volume":"290","author":"Hudson","year":"2003","journal-title":"J Am Med Assoc"},{"key":"R18-20250514","first-page":"CD011181","article-title":"Antibody therapies for lymphoma in children","volume":"1","author":"de Zwart","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-20250514","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620712443076","article-title":"Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"3","author":"Vaklavas","year":"2012","journal-title":"Ther Adv Hematol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_80_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:41:10Z","timestamp":1787067670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_80_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_80_21","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"2021-01-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}